inPractice® - Platelet Aggregation Inhibitors

Key Pharmacologic Principles and Drug-Drug Interactions in HIV Patient Care

Authors: Amanda H. Corbett, PharmD, BCPS, FCCP; Colin I. Sheffield, PharmD (More Info)
Section Editor: Eric S. Daar, MD
Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
Last Reviewed: 6/3/19 (What's New)

Summary

Active metabolite of clopidogrel may be decreased when coadministered with etravirine; avoid coadministration if possible (Table 6)^{[FDA Etravirine; DHHS ART]}
- There is also potential for clopidogrel inactivation by efavirenz^{[Hughes 2015; Xu 2013]}
Prasugrel can be coadministered with CYP 3A4 inhibitors and inducers, as well as with CYP 2B6 substrates such as nevirapine^{[FDA Prasugrel]}

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Drug-Drug Interactions, Pharmacokinetics